| 摘要 |
A pharmaceutical composition for treatment of light-injured retinal degeneration disease comprising, as an active ingredient, a dihydropyridine calcium antagonist other than nimodipine is provided. The composition of the present invention is useful for treatment of light-injured retinal degeneration, especially macula lutea degeneration including age-related macula degeneration.
|
